Trial Profile

Multi-agent Low Dose Chemotherapy (Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, Irinotecan) Followed by Maintenance Olaparib and Pembrolizumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Olaparib (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Therapeutic Use

04 Dec 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
09 Sep 2021 Status changed from not yet recruiting to recruiting.
08 Sep 2021 Planned End Date changed from 1 Feb 2029 to 1 Dec 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com